协和医学杂志2024，Vol.15Issue(2)：394-399,6.DOI:10.12290/xhyxzz.2023-0488
临床伴随药物对免疫检查点抑制剂治疗尿路上皮癌的影响研究进展
Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma
吕正钦 1赵宇豪 1郭园园 1刘贝贝 1刘建民1
作者信息
- 1. 蚌埠医科大学第一附属医院泌尿外科,安徽蚌埠 233004
- 折叠
摘要
Abstract
Immune checkpoint inhibitors(ICIs)have been approved for the treatment of urothelial carci-noma(UC).However,the use of antibiotics,proton pump inhibitors,corticosteroids,beta-blockers,metformin,and statin concomitant medications in some patients due to complications during the treatment process may affect the clinical efficacy of ICIs through different pathway,making it difficult for patients to derive clinical benefit or making it more likely to develop drug resistance.In this paper,we present a review of the effects of the above concomitant drugs on ICIs in the treatment of patients with advanced UC,with a view to provide reference for the application of individualized treatment strategies of ICIs in patients with advanced UC.关键词
伴随药物/免疫检查点抑制剂/尿路上皮癌Key words
concomitant medication/immune checkpoint inhibitors/urothelial carcinoma分类
医药卫生引用本文复制引用
吕正钦,赵宇豪,郭园园,刘贝贝,刘建民..临床伴随药物对免疫检查点抑制剂治疗尿路上皮癌的影响研究进展[J].协和医学杂志,2024,15(2):394-399,6.
